Hematopoietic Stem Cell Transplantation Market Share, 2032

Hematopoietic Stem Cell Transplantation Market - By Therapy (Allogenic, Autologous), Indication (Lymphoproliferative Disorder, Leukemia), Application (Bone Marrow & Stem Cell Transplant), Distribution Channel, End-user, Global Forecast (2023-2032)  

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.4&nbsp;&nbsp;&nbsp; Covid-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Secondary

1.6.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.1.2&nbsp;&nbsp;&nbsp;Public sources

1.6.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Hematopoietic stem cell transplantation 3600 synopsis, 2018 &ndash; 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Region trends

2.1.3&nbsp;&nbsp;&nbsp; Therapy type trends

2.1.4&nbsp;&nbsp;&nbsp; Indication trends

2.1.5&nbsp;&nbsp;&nbsp; Application trends

2.1.6&nbsp;&nbsp;&nbsp; End-user trends

Chapter 3&nbsp;&nbsp;&nbsp;Hematopoietic Stem Cell Transplantation Market Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of hematological disorders

3.2.1.2&nbsp;&nbsp;&nbsp;Rising success rate of transplantation procedures

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing number of geriatric patients

3.2.1.4&nbsp;&nbsp;&nbsp;Advancements in HSCT techniques

3.2.1.5&nbsp;&nbsp;&nbsp;Increasing awareness among physicians and patients about the benefits of HSCT

3.2.1.6&nbsp;&nbsp;&nbsp;Expanding stem cell donor registries

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of HSCT procedure

3.2.2.2&nbsp;&nbsp;&nbsp;Adverse effects associated with the transplants

3.2.2.3&nbsp;&nbsp;&nbsp;Availability of alternative therapies

3.2.2.4&nbsp;&nbsp;&nbsp;Disparities in reimbursement policies and insurance coverage for HSCT

3.2.2.5&nbsp;&nbsp;&nbsp;Difficulty associated with finding donors

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By therapy type

3.3.2&nbsp;&nbsp;&nbsp; By indication

3.3.3&nbsp;&nbsp;&nbsp; By application

3.3.4&nbsp;&nbsp;&nbsp; By end-user

3.3.5&nbsp;&nbsp;&nbsp; By region

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Technology landscape

3.7&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Global company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Therapy Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by therapy type

5.2&nbsp;&nbsp;&nbsp; Autologous transplant therapy

5.3&nbsp;&nbsp;&nbsp; Allogenic transplant therapy

Chapter 6&nbsp;&nbsp;&nbsp;Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Indication (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by indication

6.2&nbsp;&nbsp;&nbsp; Lymphoproliferative disorders

6.2.1&nbsp;&nbsp;&nbsp; Non-Hodgkin lymphoma

6.2.2&nbsp;&nbsp;&nbsp; Hodgkin lymphoma

6.2.3&nbsp;&nbsp;&nbsp; Plasma cell disorders

6.2.4&nbsp;&nbsp;&nbsp; Other lymphoproliferative disorders

6.3&nbsp;&nbsp;&nbsp; Leukemia

6.3.1&nbsp;&nbsp;&nbsp; Acute myeloid leukemia

6.3.2&nbsp;&nbsp;&nbsp; Acute lymphatic leukemia

6.3.3&nbsp;&nbsp;&nbsp; Myelodysplastic syndrome

6.3.4&nbsp;&nbsp;&nbsp; Other leukemia types

6.4&nbsp;&nbsp;&nbsp; Nonmalignant disorders

6.4.1&nbsp;&nbsp;&nbsp; Bone marrow failure

6.4.2&nbsp;&nbsp;&nbsp; Hemoglobinopathies

6.4.3&nbsp;&nbsp;&nbsp; Other nonmalignant disorders

Chapter 7&nbsp;&nbsp;&nbsp;Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Application (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by application

7.2&nbsp;&nbsp;&nbsp; Bone marrow stem cell transplant

7.3&nbsp;&nbsp;&nbsp; Peripheral blood stem cell transplant

7.4&nbsp;&nbsp;&nbsp; Cord blood transplant

Chapter 8&nbsp;&nbsp;&nbsp;Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By End-user (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by end-user

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.3&nbsp;&nbsp;&nbsp; Specialty centers

8.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Hematopoietic Stem Cell Transplantation Market Estimates and Forecast, By Region (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Pluristem Therapeutics Inc.

10.2&nbsp;&nbsp;&nbsp; Sanofi

10.3&nbsp;&nbsp;&nbsp; Taiga Biotechnologies, Inc.

10.4&nbsp;&nbsp;&nbsp; CellGenix GmbH

10.5&nbsp;&nbsp;&nbsp; Novartis AG

10.6&nbsp;&nbsp;&nbsp; Regen Biopharma Inc.

10.7&nbsp;&nbsp;&nbsp; Kiadis Pharma

10.8&nbsp;&nbsp;&nbsp; Marker Therapeutics, Inc.

10.9&nbsp;&nbsp;&nbsp; Escape Therapeutics, Inc.

10.10&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc

10.11&nbsp;&nbsp;&nbsp; Merck KGaA

10.12&nbsp;&nbsp;&nbsp; Bluebird Bio, Inc.

10.13&nbsp;&nbsp;&nbsp; Talaris Therapeutics 
&nbsp;

Hematopoietic Stem Cell Transplantation Market

Get a free sample of this report